2002•Unpublished venueRequires access

An Exploratory Study of the Combination of Monoclonal Antibodies Alemtuzumab and Rituximab in the Treatment of CD52- and CD20-Positive Chronic Lymphoid Disorders

Susan O’Brien

Abstract

Monoclonal antibodies demonstrate impressive response rates in lymphoid diseases, and treatment indications are expanding. Both alemtuzumab (Campath) (anti-CD52) and rituximab (Rituxan) (anti-CD20) are active in chronic lymphocytic leukemia (CLL) and low-grade lymphomas.

About this research paper

What this paper is about

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: CD52, Alemtuzumab, Chronic lymphocytic leukemia, Rituximab, CD20, Monoclonal antibody, Medicine, Ofatumumab